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CASE LETTERSFig 1. Multifocal infantile hemangioma: numerous super-
ficial reddish and subcutaneous blue hemangiomas at birth.
Fig 2. Magnetic resonance imaging of central nervous
system infantile hemangiomas (IHs) before (A) and after
(B) initiation of propranolol treatment. A, One spinal and
numerous intracerebral IHs with multiple gadolinium
enhancements are seen on T1-weighted images (red
arrows), some with surrounding edema (red circle).
B, Edema and contrast enhancement are no longer visible
on T1-weighted images at 6 months.Successful treatment of multifocal
intracerebral and spinal hemangiomas with
propranolol
To the Editor:Multifocal infantile hemangioma (MIHs)
is defined by the presence of at least 5 cutaneous
infantile hemangiomas (IHs). Extracutaneous involve-
ment may occur, with an estimated mortality rate
of 5%.1 Central nervous system (CNS) disease is
exceptional.
A full-termmale newbornwas hospitalizedwith 50
small superficial and deep subcutaneous IHs, without
heart failure or hepatomegaly (Fig 1). At day 2 of age,
ultrasound imaging showed a focal liver IHmeasuring
14 mm with arteriovenous shunting, a testicular
IH, and multiple hyperechogenic lesions visualized
by transfontanellar imaging. Cerebral and spinal
magnetic resonance imaging (MRI) confirmed the
presence of MIH in the brain and in 3 spinal locations,
with multiple gadolinium enhancements seen on
T1-weighted images, sometimes surrounded by slight
edema (Fig 2,A). No other visceral IHswere detected.
Thyroid functionandechocardiographywerenormal.
Treatment with propranolol 1 mg/kg daily was
started on day 8 of life. Heart rate, blood pressure,
blood glucose level, and electrocardiogram results
were normal before and after initiating propranolol
therapy. The dose was increased to 3 mg/kg daily by
day 18. There were no adverse effects and he was
discharged home on day 23.
At day 29, clinical regression of subcutaneous
lesions was observed and the liver lesion had
decreased by a few millimeters on ultrasound imag-
ing. At day 45, MRI showed a decrease in number
and size of the CNS IHs. At day 60, all subcutaneous
IHs had disappeared. At day 100, the liver and
testicular IHs were undetectable. At day 180, edema
and contrast enhancement of the brain and spinal
cord lesions were no longer visible on T1-weighted
MR images (Fig 2, B). The child’s growth and
psychomotor development were normal. One year
after starting treatment, only a few superficial cuta-
neous IHs remained and the MRI findings were
unchanged. It was planned to continue propranolol
3 mg/kg daily until 18 months of age and then
progressively reduce the dose, with repeat imaging
studies to monitor for rebound IH growth.
CNS disease in MIH is exceptional. Two cases with
extensive CNS involvement treated with systemic
corticosteroids had neurologic sequelae and side
effects.2,3 Three cases of cerebellar IH are reported4;J AM ACAD DERMATOL
Open access under CC BY-NC-ND license.2 were treated with surgical excision. Recently,
an isolated cerebellar IH associated with MIH
was treated effectively with propranolol.4 Our
case of MIH with multiple cerebral and spinal
lesionswas also successfully treatedwithpropranolol,
with rapid improvement by day 45 and disappearance
of lesions on neuroimaging at 6 months.
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Syringocystadenoma papilliferum developing
over hyperkeratosis of the nipple in a
pregnant woman
To the Editor: Syringocystadenoma papilliferum
(SCAP) is usually a solitary lesion that most
commonly occurs on the scalp.1 Rarely, lesions
have been described on the breast.1 It usually
presents at birth or develops in childhood as a
warty crusted papule. Although there is increasing
evidence for apocrine histogenesis, eccrine origin
could also be a possibility as well as derivation from
pluripotent cells.1 In approximately one third of
cases, it is associated with organoid nevus2; it has
also been described in association with nevus
comedonicus.3 Here we report, to the best of our
knowledge, the first case of SCAP developing over
hyperkeratosis of the nipple.
A 27-year-old woman in her thirty-fifth week of
first pregnancy presented with a 5-week history of
enlarging asymptomatic skin lesion on the nipple
of her right breast (Fig 1, A). She had had an
asymptomatic verrucous hyperpigmented plaque
diffusely involving the right nipple for 5 years that
was diagnosed as hyperkeratosis of the nipple
(HNA) based on biopsy findings of hyperkeratosis,
keratotic plugging, acanthosis, papillomatosis, and
a sparse perivascular lymphocytic infiltrate (Fig 1,
B). The HNA was stable until a new 0.5-cm
skin-colored papule developed over the HNA
starting in her thirtieth week of gestation. Thepatient was otherwise healthy. Shave excision of
the newly developed lesion revealed papillary
foci in continuity with the surface squamous
epithelium. These papilla had a bilayered epithe-
lium of inner columnar cells showing decapitation
secretion and outer flattened cells as well as a
fibrovascular core containing abundant plasma
cells (Fig 1, C and D). These findings were
consistent with SCAP.
First described in 1923, HNA is a benign condition
of unknown origin.4,5 It is usually bilateral, affecting
young adult women and occurring as a hyperpig-
mented verrucous lesions on the nipple (17%),
areola (25%), or both (58%).4,5 Although HNA shares
clinical and histopathologic features of epidermal
nevus, it is usually acquired after puberty and is
not associated with systemic disease. In 1938,
Levy-Franckel classified HNA into 3 types. Type 1
is an extension of epidermal nevus. Type 2 is usually
associated with several other dermatoses including
ichthyosis, Darier disease, or lymphoma. Type 3 is
the isolated nevoid variant. Hormonal factors may
contribute to its etiopathogenesis in that lesions
appear or worsen in pregnancy or with hormonal
therapy.5
There are yet no reports of an association of
HNA with SCAP or other tumors. The fact that HNA
shows features of an epidermal nevus and may
theoretically be an extension of epidermal nevus
makes the development of different neoplasms,
including SCAP, within it possible, similar to what
has been reported with nevus sebaceous and nevus
comedonicus. The basic defect producing the
hamartomatous process in epidermal nevi that
may result in immature cells capable of differenti-
ating into follicular and glandular cells and tumors
could also be playing a role in SCAP development
over HNA. This is especially true given that a recent
study demonstrated that SCAP could itself be a
hamartomatous tumor arising from pluripotent
cells.1
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